Research Article

Head and Neck Cancer Cell Death due to Mitochondrial Damage Induced by Reactive Oxygen Species from Nonthermal Plasma-Activated Media: Based on Transcriptomic Analysis

Chan Oh,1 Ho-Ryun Won,1,2 Woo Seok Kang,3 Dae-Woong Kim,3 Seung-Nam Jung,2 Mi Ae Im,2 Lihua Liu,1 Yan Li Jin,1 Yudan Piao,1 Hae Jong Kim,1 Yea Eun Kang,4 Min Jong Lee,5 Jun Young Heo,5 Sangmi Jun,6 Nam Suk Sim,2 Jeong Ho Lee,7 Kunho Song,2 Young Il Kim8, Jae Won Chang,1,2 and Bon Seok Koo1,2

1Department of Medical Science, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea
2Department of Otolaryngology-Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea
3Department of Plasma Engineering, Korea Institute of Machinery & Materials, Daejeon 34103, Republic of Korea
4Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea
5Department of Biochemistry, Chungnam National University, Daejeon 34134, Republic of Korea
6Center for Research Equipment, Korea Basic Science Institute, Cheongju 34313, Republic of Korea
7Graduate School of Medical Science and Engineering, KAIST, Daejeon 34141, Republic of Korea
8Department of Radiation Oncology, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea

Correspondence should be addressed to Young Il Kim; minesota@cnuh.co.kr, Jae Won Chang; strive1005@cnuh.co.kr, and Bon Seok Koo; bskoo515@cnuh.co.kr

Received 1 April 2021; Revised 20 May 2021; Accepted 15 June 2021; Published 7 July 2021

Academic Editor: Jayeeeta Ghose

Copyright © 2021 Chan Oh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mitochondrial targeted therapy is a next-generation therapeutic approach for cancer that is refractory to conventional treatments. Mitochondrial damage caused by the excessive accumulation of reactive oxygen species (ROS) is a principle of mitochondrial targeted therapy. ROS in nonthermal plasma-activated media (NTPAM) are known to mediate anticancer effects in various cancers including head and neck cancer (HNC). However, the signaling mechanism of HNC cell death via NTPAM-induced ROS has not been fully elucidated. This study evaluated the anticancer effects of NTPAM in HNC and investigated the mechanism using transcriptomic analysis. The viability of HNC cells decreased after NTPAM treatment due to enhanced apoptosis. A human fibroblast cell line and three HNC cell lines were profiled by RNA sequencing. In total, 1 610 differentially expressed genes were identified. Pathway analysis showed that activating transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP) were upstream regulators. Mitochondrial damage was induced by NTPAM, which was associated with enhancements of mitochondrial ROS (mtROS) and ATF4/CHOP regulation. These results suggest that NTPAM induces HNC cell death through the upregulation of ATF4/CHOP activity by damaging mitochondria via excessive mtROS accumulation, similar to mitochondrial targeted therapy.

1. Introduction

Head and neck cancer (HNC) is a common cancer that occurs in more than 650 000 people annually worldwide [1]. The regional mortality rate of lip and oral cavity cancer, a representative type of HNC, ranges from 3.9 to 8.7% in men and is currently increasing [1–3]. Despite improvements in diagnosis and treatment methods in recent decades, the 5-
year survival rate of advanced HNC remains <50% [2]. In addition, HNC has a higher mortality rate than other types of advanced cancer. Therefore, studies concerning new treatment methods or drugs for HNC are actively ongoing in various fields. In this regard, cancer mitochondria had been broadly used as the target therapy due to the discriminating structure and function between cancer cells and normal cells, such as oxidative stress, the membrane potential (ΔΨm), and metabolic activity [4]. Mitochondrial damage caused by the excessive ROS is a principal type of mitochondrial targeted therapy.

Plasma is an ionized gas that consists of electrons, ions, radicals, and energetic photons that are generated when energy is applied to a gaseous material [5–7]. Plasma medicine, which entails the clinical use of nonthermal atmospheric pressure plasma (NTP), is a rapidly growing area that could significantly provide new therapeutic applications. NTP reportedly has medical effects such as hemostasis, tissue regeneration, and cancer cell death [8–11]. In particular, NTP has anticancer effects on cervical cancer, pancreatic cancer, thyroid cancer, and HNC [6, 12–15]. However, probe-type gaseous NTP is affected by permeability depending on the application site, and there are limitations for application to internal organs [16]. To address current limitations of existing NTP treatment methods, a liquid form NTP has been devised and its effect has been proven through several studies [9, 10, 17]. Recently, liquid form NTP showed effective anticancer potential against tumor located inside the body, because its reactive oxygen species generated in the gas phase easily enter the cell membrane and destroy the cells [18]. However, many mechanisms underlying biological effects of liquid form NTP have not been elucidated.

In recent years, medical genetics research has focused on gene expression mechanisms and resulting processes in various biological samples. Here, we generated a liquid type of nonthermal plasma-activated media (NTPAM) and investigated its effects on HNC cell lines. In addition, we assessed gene expression before and after NTPAM treatment through RNA sequencing, then confirmed changes through in vitro and in vivo experiments. Our findings demonstrate an important mechanism underlying the anticancer effects of NTPAM on HNC.

2. Materials and Methods

2.1. Cell Lines and Cultures. Primary normal human fibroblasts, donated by Professor J.H. Lee (Chungnam National University, Daejeon, Republic of Korea), were used as normal epithelial cells. Human fibroblasts were cultured in Dulbecco’s modified Eagle’s medium (DMEM; WELGENE Inc., Republic of Korea) with 10% fetal bovine serum and 100 U/mL penicillin-streptomycin (Gibco, Gaithersburg, MD, USA). SNU1041 (squamous cell carcinoma of the hypopharynx) and SNU1076 (squamous cell carcinoma of the larynx) cell lines were obtained from the Korean Cell Line Bank (Seoul, Republic of Korea). SNU1041 and SNU1076 were maintained according to KCLB recommendations. The SCC25 (squamous cell carcinoma of the oral tongue) cell line was obtained from the American Type Culture Collection (Manassas, VA, USA). SCC25 was maintained in DMEM: Nutrient Mixture F-12 (WELGENE Inc.) with supplements identical to those of the other cell lines.

2.2. Generation of NTPAM. Each medium was treated using an NTP jet generated by a device composed of a quartz tube (outer diameter, 6 mm; inner diameter, 4 mm) with two electrodes (an inner stainless-steel tube electrode and an outer ground ring electrode). The inner tube electrode was also placed as a gas inlet. A high-voltage amplifier supplied input power (a few kV at 20 kHz) to the device. Discharge power varied from 10 to 24 W. The plasma jet was positioned perpendicularly over the medium in a flask, and the gas flowed from the inside of the device toward the medium surface. Helium (He) (4 standard liters per minute (slpm)) and oxygen (O2) (1 standard cubic centimeters per minute (sccm)) were used as carrier gases. For NTPAM preparation, NTP was exposed to the culture media (DMEM, RPMI 1640, and DMEM: Nutrient Mixture F-12) for various activation times, thus controlling the concentration of NTPAM. The distance between the plasma device and the bottom of the culture media was maintained at approximately 1 cm. NTPAM was prepared with 60 mL of culture media [19]. The specifications of NTPAM according to the NTP generation time are shown in Figure S1.

2.3. Cell Viability Assay. In vitro cell viabilities were estimated by the water-soluble tetrazolium salt-1 (WST-1) assay (Roche Diagnostics, Indianapolis, IN, USA). Cells were seeded in 96-well plates at 8 000 cells/well in 100 μL of the complete media. After cells had been incubated for 24 h, media were replaced with NTPAM. The treated cells were incubated at 37°C for 24 h with 5% CO2. WST-1 reagents were then added (10 μL/well) and incubated for 1 h. Plates were thoroughly shaken for 1 min, and the absorbance of formazan product at 450 nm was recorded by a microplate reader.

2.4. Annexin V-Fluorescein Isothiocyanate (FITC)/Propidium Iodine (PI) Assay. Annexin V-FITC and PI staining was performed, and cells were detected using a flow cytometer (LSRFortessa X-20; BD Biosciences, Brea, CA, USA) with an Alexa Fluor™ 488 Annexin V/Dead Cell Apoptosis Kit (Invitrogen, Carlsbad, CA, USA), in accordance with the manufacturer’s recommendation. FlowJo software version 10 (Tree Star, Ashland, OR, USA) was used to assess the percentages of cells in four populations.

2.5. RNA Preparation for Sequencing. In total, six samples per cell line were divided into three control samples and three NTPAM treatment samples. Total RNA extraction and construction of libraries were performed as described previously [19]. RNA quality involves both purity and integrity. We checked RNA purity 260/280 ratio. Ideally, the 260/280 ratio for RNA should be approximately 2.0. The RNA integrity number (RIN) is a parameter for assigning integrity values to RNA computation. We confirm total RNA integrity using an Agilent Technologies 2100 Bioanalyzer with an RIN value greater than or equal to 7.
2.6. Bioinformatics Transcriptome Analysis. Quality control analysis of raw reads obtained through sequencing was performed using FastQC (version 0.11.5; http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Preprocessing of raw data was performed using Trimmomatic software (0.32; http://www.usadellab.org/cms/?page=trimmomatic), and trimmed reads were mapped to a reference genome (UCSC Homo sapiens reference genome; GRC37/hg19) using HISAT2 (version 2.0.5; https://daehwankimlab.github.io/hisat2/). After read mapping, transcript assembly was performed using StringTie software (version 1.3.3b; https://ccb.jhu.edu/software/stringtie/). Expression profile values were then obtained for each sample for known transcripts, and read counts and fragments per kilobase per million mapped reads (FPKM) values were determined. For differentially expressed gene analysis, genes with fold change (FC) \( \geq 2 \) or \( \leq -1.6 \) and independent t-test raw \( p \) value \(< 0.05\) were extracted using FPKM analysis. Heat maps were generated using PermutMatrix (version 1.9.3; http://www.atgc-montpellier.fr/permutmatrix/).

Gene ontology analysis was performed by using gene ontology software (http://geneontology.org/). To include only significant results, the false discovery rate threshold was set to \( p < 0.05 \). Pathway analysis was performed using Ingenuity Pathway Analysis (IPA) (Qiagen). Genes related to canonical pathways extracted through the Ingenuity Pathway Knowledge Base were further analyzed.

2.7. RNA Isolation and Real-Time qPCR. Total RNA was extracted using a RNeasy Mini Kit (Qiagen). cDNA was synthesized with 1 \( \mu \)g total RNA and TOPscriptTMRTDryMIX (Enzymics, Daejeon, Korea), in agreement with the manufacturer’s instructions. Amplification was carried out using SFGreen™-Cyan qPCR Master Mix (2X)-Low ROX (SFc probe, Giheung-gu, Republic of Korea). Melting curve analysis was performed. PCR primer sequences are shown in supplementary Materials Table S1.

2.8. siRNA Transfection. Cells were seeded in six-well plates at \( 3 \times 10^5 \) cells/well. After 24h of incubation, cells were transfected with 60nmol siRNA using Lipofectamine RNAi MAX reagent (Invitrogen). Negative siRNA was used as a negative control. ATF-4 siRNA (sc-35112, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was a pool of three unique siRNA duplexes with the following sequences shown in supplementary Materials Table S2.

2.9. Western Blot. Cells were lysed using RIPA buffer with a protease inhibitor cocktail (Roche Applied Science, Vienna, Austria). Total protein was quantified using a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). Samples were separated by SDS-PAGE and transferred to PVDF membranes (Millipore, Burlington, MA, USA). Membranes were blocked in TBS with Tween containing 5% skim milk. They were then incubated with specific primary antibodies on a gentle shaker overnight at 4°C. The following primary antibodies were used for Western blotting: antibodies against poly (ADP-ribose) polymerase (PARP), Caspase 3, cytochrome c oxidase (Cox) IV, Succinate dehydrogenase iron-sulfur subunit B (SDHB), ATF4, CHOP, and \( \beta \)-actin (all 1 : 1000; Cell Signaling Technology, Danvers, MA, USA); Adenosine triphosphate (ATP) 5A and ubiquinol-cytochrome c reductase core protein 2 (UQRC2) (both 1 : 1000; Abcam, Cambridge, UK); NADH-ubiquinone oxidoreductase chain 6 (ND6) (1 : 1000; Biocompare, San Francisco, CA, USA); and B-cell lymphoma 2 (Bcl-2) (1 : 1000; Santa Cruz Biotechnology). Membranes were incubated with secondary antibodies on a gentle shaker for 1h at room temperature. Signals were observed using an ECL kit (Bio-Rad Laboratories, Hercules, CA, USA). Images were quantified with ImageJ software (version 1.53a; National Institutes of Health, Bethesda, MD, USA), and the normalization results were presented as numbers in the image.

2.10. Oxygen Consumption Rate (OCR) Measurement. The OCR was determined using a Seahorse XF-24 analyzer (Seahorse Bioscience Inc., North Billerica, MA, USA). Briefly, thyroid cells were grown in XF-24 plates (2 x 10^5 cells in 200 \( \mu \)L of growth medium per well) and incubated in an incubator at 37°C with 5% \( \text{CO}_2 \) for 24h. A sensor cartridge was positioned into calibration buffer supplied by Seahorse Bioscience and incubated at 37°C in an incubator without \( \text{CO}_2 \) for 24h before the experiment. Immediately before measurement, the cells were washed and incubated in assay medium at 37°C for 1h in an incubator without \( \text{CO}_2 \). Oligomycin A (20 \( \mu \)g/mL), an ATP synthase (complex V) inhibitor, was injected to measure cellular ATP production. Carbonyl cyanide m-chlorophenyl hydrizine (optimized concentration, 50 \( \mu \)M), an uncoupling agent, was used to measure maximal respiration by disrupting the mitochondrial membrane potential. Rotenone (20 \( \mu \)M), a complex I inhibitor, was injected to restrain mitochondrial respiration and allow the calculation of nonmitochondrial respiration. The OCR was shown by a sensor cartridge and calculated using Seahorse XF-24 software.

2.11. Transmission Electron Microscopy. Cells were pelleted via centrifugation and fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) at 4°C. After 2h, the pellets were rinsed three times in 0.1 M phosphate buffer and then post-fixed in 1% osmium tetroxide at 4°C for 1–2h, followed by three washes in phosphate buffer. The pellets were dehydrated through a series of ethanol solutions and exposed to two changes of propylene oxide. After the dehydration process, the pellets were infiltrated with 2:1, 1:1, and 1:2 mixtures of EMbed 812 resin and propylene oxide for 1h each time. They were finally embedded in 100% EMbed 812 resin. After the resin had been polymerized for 24–48h at 60°C, ultrathin plastic sections (80 nm thick) were cut at room temperature using a Leica EM UC6 ultramicrotome (Leica Microsystems GmbH, Wetzlar, Germany) and collected on 200-mesh carbon-coated grids. The grids were poststained with 2% uranyl acetate and 1% lead citrate at room temperature for 15 and 5 min, respectively. A Zeiss LEO912AB 120 kV transmission electron microscope (Carl Zeiss, Oberkothen, Germany) and a FEI Tecnai G2 Spirit Twin 120 kV transmission electron microscope (FEI Company, Columbia, MD, USA) were used for transmission electron microscopy observations.
2.12. Mitochondrial ROS (mtROS) Measurement. The MitosOX fluorescent probe (Thermo Fisher Scientific) was used to assess mitochondrial superoxide. Cells were co-treated with or without NTPAM and N-acetyl cysteine (NAC) (2 and 5 mM, respectively), then incubated at 37°C for 24 h. After treatment, cells were stained with MitosOX (5 μM) in Hank’s balanced salt solution for 15 min. Fluorescence-stained cells (2 × 10^5) were analyzed via flow cytometry (LSRFortessa X-20; BD Biosciences), and FlowJo software version 10 (Tree Star) was used to analyze the proportions of cells.

2.13. Xenograft Animal Model and Experimental Protocol. Ten healthy male BALB/c nude mice (Saerombio, Uiwang-si, Republic of Korea) were used in this experiment. The experimental procedures were allowed by the Chungnam University School of Medicine Animal Experiment Ethics Committee (202006A-CNU-112). Ten mice were randomly separated into a control group and NTPAM treatment group. SNU1041 cells (5 × 10^6 cells/mL) were prepared and injected subcutaneously into the upper thigh of the hind legs of each mouse. Gross tumor formation was confirmed on the 10th day after injection. Next, 100 μL intratumoral injections of medium in the control group and NTPAM in the experimental group were administered once daily for 11 days. The same amounts of food and water were provided to each mouse, and gross tumor volume was measured at 3-day intervals after treatment. After 3 weeks of tumor cell injection, mice were sacrificed and the tumors were dissected.

2.14. Histological and Immunohistochemical Analysis. Excised tumor specimens were fixed in 4% paraformaldehyde solution (Thermo Fisher Scientific). Paraffin blocks were prepared using a standard paraffin sample preparation method; then, tissues were stained with hematoxylin and eosin using a standard protocol. Immunohistochemical analysis was performed as described previously [19]. Sections were incubated with antibodies against Ki-67 (1: 500; Bethyl Laboratories, Cambridge, UK), ATF4 (1:200; Santa Cruz Biotechnology), and CHOP (1:200; Cell Signaling Technology). Automatic digital slide scanner (Panoramic MIDI, 3DHISTECH, Budapest, Hungary) was used to analyze the image. Three fields were randomly selected from each sample, and their optical densities were quantified using ImageJ software (version 1.53a; National Institutes of Health).

2.15. Statistics. All experiments were conducted three times, and the mean values were analyzed. Statistical analysis and graphical plots were assessed using Prism 8.0.1 (GraphPad). Data are expressed as means ± standard deviations, and the significance of between-group differences was evaluated using two-tailed Student’s t-tests. p < 0.05 was considered to reveal statistical significance (*p < 0.05; **p < 0.01; and ***p < 0.001).

3. Results

3.1. NTPAM Induced Apoptotic Cell Death in HNC Cell Lines. First, we investigated whether NTPAM affected the cell viability of HNC cell lines. Optical microscopy revealed that the number of cells decreased when the SNU1041 and SNU1076 HNC cell lines were treated with NTPAM produced by 2 h of NTP activation (Figure 1(a)). Before and after NTPAM treatment, the WST-1 assay was used to evaluate the viabilities of normal control cells (human fibroblasts) and three HNC cell lines (SNU1041, SNU1076, and SCC25). Cytotoxicity was not observed in the normal control cell line, but cell viability was significantly reduced in HNC cell lines in a manner dependent on NTP activation time (Figure 1(b)). All subsequent experiments were conducted under conditions involving 24 h of incubation with NTPAM that was generated by 2 h of NTP activation. After NTPAM treatment, Annexin V-FITC/PI analysis showed statistically significant enhancements of the fractions of cells corresponding to early apoptotic cells (FITC+/PI-) and late apoptotic cells (FITC+/PI+) (Figures 1(c) and 1(d)). Figure 1(e) shows apoptosis-related markers assessed after exposure to NTPAM. Notably, the protein levels of cleaved PARP increased, whereas those of pro-Caspase 3 and Bcl-2 decreased. These results suggested that NTPAM selectively induces apoptosis in HNC cells.

3.2. Transcriptomic Analysis of HNC Cells after NTPAM Treatment. A normal control cell line (human fibroblasts) and three HNC cell lines (SNU1041, SNU1076, and SCC25) were divided into NTPAM-treated and nontreated groups, and three samples of each group were collected. RNA sequencing was conducted to determine the effects of NTPAM on the transcriptome of each cell line (Figure 2(a)). In total, 1.610 differentially expressed genes (DEGs) were identified depending on NTPAM treatment status (Figure 2(b)). Based on these data, the level of similarity was expressed using multidimensional scaling (Figure 2(c)). In the human fibroblast cell line, there were no noticeable changes in gene expression according to NTPAM treatment status. However, as shown in Figure 2(c), comparisons between the NTPAM-treated (red circle) and nontreated groups (Blue circle) of HNC cell lines showed consistent shifts after NTPAM treatment. Up- and downregulated genes were identified according to NTPAM treatment status in each cell line using FC ≥ 2 or ≤ -1.6 and p ≤ 0.05. Synthesis of the results revealed that 119 genes were upregulated and 213 genes were downregulated (Figure 2(d)). Gene ontology analysis was then performed to derive the biological processes and molecular functions of the identified genes, and the top 13 functional processes were identified. The findings showed that NTPAM treatment regulated mechanisms related to cell death and cell cycle. In addition, there was a significant association with the regulation of protein kinase R-like endoplasmic reticulum kinase (PERK), known as an endoplasmic reticulum (ER) stress sensor. This regulation was closely related to an altered cell stress response (Figure 2(e)).

3.3. IPA of Gene Expression Profiles in HNC after NTPAM Treatment. IPA was performed to identify the mechanism and key factors that may be linked to the DEGs identified in the previous experiment. IPA confirmed the molecular pathways that were up- or downregulated in NTPAM-treated and nontreated groups (Figure 3(a)). Additionally,
Figure 1: Continued.
relevant transcriptional regulators were identified through upstream regulator analysis. In particular, ATF4 and DNA damage-inducible transcript 3 (DDIT3), also known as CHOP, were identified as the most relevant upstream regulators (Figure 3(b)). These results confirmed that ATF4 and CHOP were major upstream transcriptional regulators of the network of mechanical signalling pathways that differed between NTPAM-treated and nontreated groups (Figure 3(c)).

3.4. ATF4 And CHOP Are Key Regulators of NTPAM-Induced HNC Cell Death. Transcriptomic analysis indicated that NTPAM induced upregulation of the PERK-related unfolded protein response pathway in HNC cell lines. This suggests that NTPAM may cause cell death due to ER stress. In addition, overexpression of the ATF4/CHOP mechanism (identified through upstream regulator analysis) is reportedly influencing the survival and death of cancer cells [21]. Recently, ATF4 has been identified as a major regulator of the mitochondrial stress response [22]. Therefore, we speculated that the phenomenon of NTPAM-induced HNC cell death may be related to mitochondrial stress response and damage.

To assess mitochondrial function in HNC cell lines after NTPAM treatment, we analyzed the OCR. Compared with nontreated cells, the treated cells exhibited reduced mitochondrial function (Figures 5(a) and 5(b)) and elevated numbers of disrupted mitochondria (Figure 5(c)). We also examined the human fibroblasts when treated with NTPAM. OCR before and after NTPAM treatment did not differ in human fibroblasts (Figures S2a and b). Furthermore, RNA sequencing analysis showed that the FPKM values of mitochondrial oxidative phosphorylation-related genes tended to decrease after NTPAM treatment. In particular, NDUF51 and SDHA were significantly reduced in both SNU1041 and SNU1076 cell lines (Figure 5(d)). In addition, the protein levels of enzymes involved in oxidative phosphorylation were examined by Western blotting. After NTPAM treatment, the levels of the Cox IV (complex IV), UQCRCC2 (complex III), and SDHB (complex II) components of the oxidative phosphorylation complex were reduced in SNU1041 and SNU1076 cell lines (Figure 5(e)). Thus, our data revealed that NTPAM treatment induces mitochondrial dysfunction in HNC cells through mitochondrial damage.

3.5. NTPAM Induces Mitochondrial Damage in HNC Cells. Mitochondria play an important role in cellular metabolism, thus influencing the survival and death of cancer cells [21]. NTPAM generated by activation of NTP for 2 h and added to cultures for 24 h. (e) NTPAM reduced pro-Caspase 3/Bcl-2 expression and induced cleaved-PARP expression in HNC cell lines, as determined by Western blotting. NS: not significant; *** p ≤ 0.001.

Figure 1: NTPAM induced apoptotic cell death in HNC cell lines. (a) Microscopic evaluation of HNC cell morphology after treatment with NTPAM. (b) Cell viability was analyzed using the WST-1 assay after treatment with NTPAM generated by activation of NTP for 2 h. NTPAM significantly reduced the viabilities of HNC cell lines in an NTP activation-dependent manner. (c, d) Apoptosis was analyzed using the Annexin V-FITC/PI assay. NTPAM significantly enhanced apoptotic cell death in SNU1041 and SNU1076 cell lines. NTPAM was generated by activation of NTP for 2 h and added to cultures for 24 h. (e) NTPAM reduced pro-Caspase 3/Bcl-2 expression and induced cleaved-PARP expression in HNC cell lines, as determined by Western blotting. NS: not significant; *** p ≤ 0.001.

<table>
<thead>
<tr>
<th>NTPAM</th>
<th>SNU1041</th>
<th>SNU1076</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PARP</td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>+</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td></td>
<td>Cleaved PARP</td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>+</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>Pro-caspase-3</td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>+</td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td></td>
<td>Bcl-2</td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>+</td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td></td>
<td>β-Actin</td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>+</td>
<td>0.7</td>
<td>0.7</td>
</tr>
</tbody>
</table>
Figure 2: Continued.
scavenges mtROS, including intracellular ROS. We found that the NTPAM-induced enhancement of mtROS levels was mitigated by NAC treatment (Figures 6(a) and 6(b)). In addition, NTPAM-induced enhancements of ATF4 and CHOP protein levels were both reduced in an NAC concentration-dependent manner (Figure 6(c)). Finally, cell viability was significantly reduced after NTPAM treatment, but this effect was reversed by NAC treatment (Figure 6(d)).

3.7. NTPAM Suppressed HNC Progression in a Mouse Xenograft Model. To evaluate the in vivo effects of NTPAM on HNC, experiments were performed using a mouse xenograft model established by subcutaneous injection of SNU1041 cells (5 x 10^6 cells/mL). After 10 days, tumor growth was visually confirmed, and NTPAM (100 μL) was then injected intratumorally once daily (Figures 7(a) and 7(b)). Changes in tumor volume were recorded during the experiment, and mice were sacrificed on the 21st day (Figures 7(a) and 7(b)). Compared to the NTPAM-treated group, the tumor volume in the control group was significantly larger during the experiment period (Figure 7(c)). On the 21st day, analysis of tumors harvested from sacrificed mice showed that the tumor volume and weight were significantly lower in the NTPAM-treated group (Figures 7(c)–7(e)).

Hematoxylin and eosin (H&E) staining of tumor tissue showed excessive cell proliferation of tumor cells in the control group, whereas hyalinization was observed due to the death of cancer cells in the NTPAM-treated group (Figure 7(f)). Immunohistochemical staining was used to evaluate the expression levels of Ki-67, ATF4, and CHOP in tumor tissue. Ki-67 expression was high in the control group. In contrast, the expression levels of ATF4 and CHOP were elevated in tumor tissue after NTPAM treatment. These results indicated that NTPAM attenuated the progression of HNC in vivo through elevated expression levels of ATF4 and CHOP (Figures 7(f) and 7(g)).

The findings in this study suggested that NTPAM induces mtROS enhancement, resulting in mitochondrial damage and increased HNC cell apoptosis through the ATF4/CHOP signaling pathway (Figure 7(h)).
**Figure 3:** IPA of gene expression profiles in HNC after NTPAM treatment. (a) Top relevant canonical pathways associated with NTPAM treatment by core analysis. (b) List of most potent transcription regulators through upstream regulator analysis. ATF and CHOP (DDIT3) were identified as the most relevant upstream regulators with NTPAM treatment. (c) String network of mechanical signaling pathways related to ATF4 and CHOP.
Despite progress in the diagnosis and treatment of HNC, its incidence and mortality continue to increase [23, 24]. Surgery, chemotherapy, and radiation therapy for advanced HNC are applied as single or combination treatments, but there has been no substantial improvement in the 5-year survival rates of some HNC types [2]. Precision medicine has been used to develop targeted therapeutics in recent years. However, there are several limitations such as treatment resistance, side effects, and tumor heterogeneity [25–27]. A new type of anticancer treatment approach is needed to overcome these therapeutic limitations.

Plasma medicine is rapidly becoming an important potential treatment field. NTP is effective for regenerating damaged tissue epithelium and thus protects normal tissue in various disease models [7, 9, 10, 28]. This suggests that the use of NTP as an alternative therapy can overcome the

4. Discussion

However, there are several limitations such as treatment resistance, side effects, and tumor heterogeneity [25–27]. A new type of anticancer treatment approach is needed to overcome these therapeutic limitations.

Plasma medicine is rapidly becoming an important potential treatment field. NTP is effective for regenerating damaged tissue epithelium and thus protects normal tissue in various disease models [7, 9, 10, 28]. This suggests that the use of NTP as an alternative therapy can overcome the...
Figure 5: Continued.
limitations of existing anticancer treatment due to toxicity in normal cells.

In particular, NTPAM is useful because it has an anticancer effect similar to that of existing NTP and can be directly applied to tumors [29–31]. The anticancer effects of NTP are broadly related to mechanisms such as apoptosis induction through ROS generation and cytoskeletal modulation [6, 31, 32], but the detailed underlying mechanisms are unclear. To our knowledge, there have been few studies concerning the mechanism by which NTPAM mediates its anticancer effects. Therefore, our study is important in that it confirms the anticancer effects of NTPAM in HNC cell lines and provides transcriptomics-related insights concerning the underlying mechanisms of these anticancer effects.

ATF4 is a transcription factor expressed in the context of sustained ER stress, which induces adaptation to stress conditions [20, 33]. It is also related to the regulation of mitochondrial stress [22]. CHOP regulates the expression of proapoptosis-related genes and is activated by ATF4 [34, 35]. The excessive accumulation of mtROS induces mitochondrial permeability transition, thus causing damage through osmotic expansion of the mitochondrial matrix [36, 37]. This mechanism is an important component of mitochondrial targeted therapy [36]. Here, we found that NTPAM induced the enhancement of mtROS in HNC cells, as well as mitochondrial damage. IPA analysis revealed that the expression patterns of ATF4 and CHOP, major upstream regulators of the NTPAM-induced anticancer effect, were altered by treatment with NAC, a ROS scavenger. Therefore, we hypothesized that the anticancer mechanism of NTPAM involved enhanced mitochondrial stress and mitochondrial damage due to the accumulation of mtROS, which led to the overexpression of both ATF4 and CHOP.

Figure 5: NTPAM induces mitochondrial damage in HNC cells. (a, b) OCR measurement by Seahorse XF-24 analyzer in HNC cell lines (SNU1041 and SNU1076). A significant reduction in OCR was evident after NTPAM treatment. (c) Transmission electron microscopic examination of HNC cell lines before and after NTPAM treatment. Normal mitochondria were disrupted after NTPAM treatment (normal mitochondria: white arrow, dysmorphic mitochondria: black arrow). (d) FPKM values of the oxidative phosphorylation-related genes of SNU1041 and SNU1076 in RNA sequencing data. In SNU1041, the FPKM values of FADD, NDUFS1, NDUFV3, SDHA, UQCRC2, and NDUFV2 were significantly reduced after NTPAM treatment. In SNU1046, the FPKM values of NDUFS1 and SDHA were significantly reduced. (e) Western blotting analyses of oxidative phosphorylation complex protein levels in HNC cell lines. Protein levels of Cox IV (complex IV), UQCRC2 (complex III), and SDHB (complex II) were reduced after NTPAM treatment in SNU1041 and SNU1076 cell lines. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
Figure 6: NTPAM-induced enhancement of mtROS is associated with overexpression of ATF4 and CHOP via mitochondrial damage. (a, b) mtROS expression levels after NTPAM and NAC treatments were evaluated by measurement of mitochondrial superoxide. mtROS levels increased significantly with NTPAM treatment in SNU1041 and SNU1076 cell lines. This enhanced mtROS expression was significantly reduced by application of the ROS scavenger NAC. (c) After treatment with NAC, changes in ATF4 and CHOP protein levels were evaluated by Western blotting. NTPAM treatment increased ATF4 and CHOP levels, but these changes were mitigated by NAC treatment. (d) WST-1 assays showed that the reduced cell viability after NTPAM treatment was alleviated by NAC treatment. **p ≤ 0.01; ***p ≤ 0.001.
Figure 7: Continued.

(a) SNU1041 tumor cell injection followed by daily NTPAM treatment with intratumoral injection. 
(b) Day 21 images showing control (Ctrl) and NTPAM groups.

(c) Graph showing tumor volume over time (days) for Ctrl and NTPAM groups.

(d) Representative images showing H&E, Ki-67, ATP4, and CHOP staining for Ctrl and NTPAM groups.

(e) Bar graph comparing tumor weight (g) for Ctrl and NTPAM groups.

(f) Figures showing the staining results for H&E, Ki-67, ATP4, and CHOP.
Mitochondria are organelles responsible for energy metabolism, cellular redox/calcium homeostasis, and cell death regulation in normal cells [38, 39]. Furthermore, mitochondria are also important mediators of tumorigenesis because they regulate apoptosis and are thus involved in the formation of neoplasms (through the alteration of mitochondrial function) [36, 40]. Cancer cells undergo metabolic reprogramming through changes in mitochondrial function, and tumorigenesis is promoted by changes in cancer cell-specific metabolites [41]. Mitochondrial targeted therapy is a unique approach that differs considerably from existing anticancer drugs and can enable individualized treatment of patients with carcinomas [36]. The anticancer effects of NTPAM are closely related to the regulation of ATF4 and CHOP activities, in which transcriptome analysis revealed that they were related to the mitochondrial stress response. Experimental analysis showed that these effects were mediated by mitochondrial damage. Therefore, NTPAM is presumably suitable as a cancer-specific mitochondrial targeting agent. To establish the generalizability of this mechanism, additional research is needed to determine whether the same phenomenon appears in other cancer types.

Here, we performed an in vivo experiment involving an intratumoral injection method, which showed positive results supporting its potential use in clinical practice. In particular, NTPAM can be applied to HNC tumors in various forms such as gargle or spray, in addition to a liquid injection method. Therefore, NTPAM offers an alternative treatment for HNC cancer that is refractory to existing treatment. However, for future clinical applications, large-scale experiments with medium and large animals must be performed. Further studies are also needed to optimize the dose of NTPAM and establish its safety characteristics.

5. Conclusions

In conclusion, NTPAM induces the accumulation of mtROS in HNC cells. Mitochondrial damage caused by this accumulation of mtROS induces the overexpression of both ATF4 and CHOP, thereby increasing apoptosis. NTPAM offers a new alternative therapy that can overcome limitations involving toxic effects in normal cells and resistance to conventional cancer therapy.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Authors’ Contributions

Chan Oh and Ho-Ryun Won contributed equally to this work as 1st authors. Young Il Kim and Jae Won Chang contributed equally to this work.
Acknowledgments

This work was supported by the research fund of Chungnam National University (2020-2021), the Korea Health Technology R & D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare (grant number HR20C0025) and the National Research Foundation of Korea (NRF) (grant number 2019R1C1C1006453 to Ho-Ryun Won; 2018R1D1A3B07051260 to Young Il Kim; 2016R1D1A1B0493211215 to Jae Won Chang; and 2019R1A2C108412512 to Bon Seok Koo).

Supplementary Materials

Supplementary 1. Figure S1: nonthermal plasma-activated media (NTPAM) generation system and specification. Figure S2: oxygen consumption rate (OCR) measurement in human fibroblasts after NTPAM treatment.

Supplementary 2. Supplementary Table S1: PCR primer sequence. Supplementary Table S2: siRNA sequence.

References

cancer incidence, mortality, years of life lost, years lived with
disability, and disability-adjusted life-years for 29 cancer
groups, 1990 to 2017: a systematic analysis for the Global Bur-
den of Disease study,” JAMA oncology, vol. 5, no. 12, pp. 1749–
1768, 2019.
apy: treating cancer with specificity,” European journal of
[26] C. Widakowich, G. de Castro, E. de Azambuja, P. Dinh, and
A. Awada, “Review: side effects of approved molecular targeted
therapies in solid cancers,” The Oncologist, vol. 12, no. 12,
[27] S. Loges, T. Schmidt, and P. Carmeliet, “Mechanisms of resis-
tance to anti-angiogenic therapy and development of third-
generation anti-angiogenic drug candidates,” Genes Cancer,
“Non-thermal atmospheric plasma ameliorates imiquimod-
induced psoriasis-like skin inflammation in mice through
inhibition of immune responses and up- regulation of PD-
L1 expression,” Scientific reports, vol. 7, no. 1, article
15564, 2017.
[29] J. Chauvin, F. Judée, M. Yousfi, P. Vicendo, and N. Merbah,
“Analysis of reactive oxygen and nitrogen species generated
in three liquid media by low temperature helium plasma jet,”
man, and M. Keidar, “Stabilizing the cold plasma-stimulated
medium by regulating medium’s composition,” Scientific reports,
vol. 6, no. 1, article 26016, 2016.
[31] K. Anzai, T. Aoki, S. Koshimizu, R. Takaya, K. Tsuchida, and
T. Takajo, “Formation of reactive oxygen species by irradiation
of cold atmospheric pressure plasma jet to water depends on
the irradiation distance,” Journal of clinical biochemistry and
[32] K. Iuchi, Y. Morisada, Y. Yoshino et al., “Cold atmospheric-
pressure nitrogen plasma induces the production of reactive
nitrogen species and cell death by increasing intracellular cal-
cium in HEK293T cells,” Archives of biochemistry and biophys-
[33] A. H. Schonthal, “Endoplasmic reticulum stress: its role in dis-
ease and novel prospects for therapy,” Scientifica (Cairo),
[34] S. Dey, T. D. Baird, D. Zhou, L. R. Palam, D. F. Spandau, and
R. C. Wek, “Both Transcriptional Regulation and Transla-
tional Control of ATF4 Are Central to the Integrated Stress
Response,” Journal of Biological Chemistry, vol. 285, no. 43,
endoplasmic reticulum stress,” Cell Death and Differentiation,
[36] S. Fulda, L. Galluzzi, and G. Kroemer, “Targeting mitochon-
dria for cancer therapy,” Nature Reviews. Drug Discovery,
membrane permeabilization in cell death,” Physiological
mitochondrial stress response in human cancer progression,”
Experimental Biology and Medicine, vol. 245, no. 10,
vital functions of apoptotic effectors,” Cell Death and Differen-
[40] V. Gogvadze, S. Orrenius, and B. Zhivotovsky, “Mitochondria
in cancer cells: what is so special about them?,” Trends in cell
[41] S. Vyas, E. Zaganjor, and M. C. Haigis, “Mitochondria and